Supplementary Table S2 from A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance

Abstract

<p>Supplemental Table S2. Relative phospho-protein expression with and without FGF2 treatment.</p>